An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Equillium Provides Timing Update on Conference Presentations
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Equillium, Inc. (NASDAQ: EQ), a clinical-stage biotechnology company, announced updates for its conference participation. The company will hold a virtual fireside chat at the SVB Leerink Virtual Global Healthcare Conference on February 17, 2022, at 2:20 pm ET, with a live webcast available on its website. Additionally, the dates for the American Society of Transplantation and Cellular Therapy conference have been rescheduled to April 23-26, 2022, and will be held both virtually and in-person in Salt Lake City. Equillium is focused on developing itolizumab for severe autoimmune and inflammatory disorders.
Positive
None.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations.
Equillium will now participate in a virtual fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference on Thursday, February 17, 2022, at 2:20 pm Eastern Time. A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.
Dates for the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research, which were originally scheduled for February have been changed to April 23 – 26, 2022. The conference will take place virtually and in person at the Salt Palace Convention Center in Salt Lake City.
About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD) and lupus/lupus nephritis.
What is Equillium's conference presentation schedule for 2022?
Equillium will participate in a virtual fireside chat at the SVB Leerink Virtual Global Healthcare Conference on February 17, 2022, and the American Society of Transplantation and Cellular Therapy conference on April 23-26, 2022.
Where can I watch Equillium's presentations?
Live webcasts of Equillium's presentations will be available on their website under the 'Investors' section.
What is itolizumab being developed for?
Itolizumab is being developed by Equillium for severe autoimmune and inflammatory disorders, including acute graft-versus-host disease and lupus.
